MA28102A1 - Formulations pharmaceutiques, methodes et schemas d'administration pour le traitement et la prevention des syndromes coronariens aigus - Google Patents

Formulations pharmaceutiques, methodes et schemas d'administration pour le traitement et la prevention des syndromes coronariens aigus

Info

Publication number
MA28102A1
MA28102A1 MA28951A MA28951A MA28102A1 MA 28102 A1 MA28102 A1 MA 28102A1 MA 28951 A MA28951 A MA 28951A MA 28951 A MA28951 A MA 28951A MA 28102 A1 MA28102 A1 MA 28102A1
Authority
MA
Morocco
Prior art keywords
methods
prevention
treatment
pharmaceutical formulations
acute coronary
Prior art date
Application number
MA28951A
Other languages
English (en)
Inventor
Charles L Bisgaier
Wendi V Rodrigueza
Narendra D Lalwani
Daniel Hartman
Jan Johansson
Original Assignee
Esperion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esperion Therapeutics Inc filed Critical Esperion Therapeutics Inc
Publication of MA28102A1 publication Critical patent/MA28102A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Formulations pharmaceutiques, méthodes et schémas d'administration pour le traitement et la prévention des syndromes coronariens aigus La présente invention propose des méthodes et formulations pour le traitement et la prévention des syndromes coronariens aigus. Les méthodes de la présente invention fournissent des doses sûres et efficaces d'un complexe Apolipoprotéine A-1 Milano:phospholipide pour réduire et stabiliser la plaque athérosclérotique. Des formulations pharmaceutiques des complexes Apo-A-I Milano: phospholipide sont également proposées.
MA28951A 2003-10-20 2006-04-20 Formulations pharmaceutiques, methodes et schemas d'administration pour le traitement et la prevention des syndromes coronariens aigus MA28102A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51311603P 2003-10-20 2003-10-20
US51701603P 2003-11-03 2003-11-03
US57112904P 2004-05-14 2004-05-14

Publications (1)

Publication Number Publication Date
MA28102A1 true MA28102A1 (fr) 2006-08-01

Family

ID=34557347

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28951A MA28102A1 (fr) 2003-10-20 2006-04-20 Formulations pharmaceutiques, methodes et schemas d'administration pour le traitement et la prevention des syndromes coronariens aigus

Country Status (23)

Country Link
US (2) US7435717B2 (fr)
EP (1) EP1677597B1 (fr)
JP (1) JP2007509157A (fr)
KR (3) KR20060080227A (fr)
AR (1) AR046126A1 (fr)
AU (2) AU2004284932A1 (fr)
CA (1) CA2542726C (fr)
CO (1) CO5690611A2 (fr)
CR (1) CR8352A (fr)
EA (1) EA010134B1 (fr)
EC (1) ECSP066516A (fr)
ES (1) ES2449719T3 (fr)
GE (1) GEP20094601B (fr)
IL (1) IL174301A (fr)
MA (1) MA28102A1 (fr)
MX (1) MXPA06004362A (fr)
NO (1) NO339456B1 (fr)
NZ (1) NZ545939A (fr)
OA (1) OA13272A (fr)
PA (1) PA8615301A1 (fr)
PE (1) PE20050438A1 (fr)
RS (1) RS20060273A (fr)
WO (1) WO2005041866A2 (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8529430B2 (en) 2002-08-01 2013-09-10 Cardiokinetix, Inc. Therapeutic methods and devices following myocardial infarction
US9694121B2 (en) 1999-08-09 2017-07-04 Cardiokinetix, Inc. Systems and methods for improving cardiac function
US8500795B2 (en) 1999-08-09 2013-08-06 Cardiokinetix, Inc. Retrievable devices for improving cardiac function
US8388672B2 (en) 1999-08-09 2013-03-05 Cardiokinetix, Inc. System for improving cardiac function by sealing a partitioning membrane within a ventricle
US10307147B2 (en) 1999-08-09 2019-06-04 Edwards Lifesciences Corporation System for improving cardiac function by sealing a partitioning membrane within a ventricle
US7674222B2 (en) 1999-08-09 2010-03-09 Cardiokinetix, Inc. Cardiac device and methods of use thereof
US8257428B2 (en) 1999-08-09 2012-09-04 Cardiokinetix, Inc. System for improving cardiac function
US9332992B2 (en) 2004-08-05 2016-05-10 Cardiokinetix, Inc. Method for making a laminar ventricular partitioning device
US9332993B2 (en) 2004-08-05 2016-05-10 Cardiokinetix, Inc. Devices and methods for delivering an endocardial device
US9078660B2 (en) 2000-08-09 2015-07-14 Cardiokinetix, Inc. Devices and methods for delivering an endocardial device
US10064696B2 (en) 2000-08-09 2018-09-04 Edwards Lifesciences Corporation Devices and methods for delivering an endocardial device
AU2002362612B2 (en) * 2001-09-28 2007-11-15 Cedars-Sinai Medical Center Prevention and treatment of restenosis by local administration of drug
AU2003239489A1 (en) * 2002-05-17 2003-12-02 Esperion Therapeutics, Inc. Method of treating dyslipidemic disorders
JP2007531537A (ja) * 2004-04-06 2007-11-08 セダーズ−シナイ　メディカル　センター アポリポタンパク質ａ−ｉおよびアポリポタンパク質ａ−ｉｍｉｌａｎｏをコードする組換えアデノ随伴ウイルスベクターによる血管疾患の予防および処置
SMP200800012B (it) * 2005-07-22 2008-02-27 Procter & Gamble Composizioni per ridurre l'incidenza di aritmia indotta da farmaco
WO2007130724A2 (fr) * 2006-02-06 2007-11-15 Northwind Ventures Systèmes et procédés de réduction de volume
US20070254832A1 (en) * 2006-02-17 2007-11-01 Pressler Milton L Methods for the treatment of macular degeneration and related eye conditions
AU2007224175A1 (en) * 2006-03-03 2007-09-13 Activbiotics Pharma Llc Treatment of atherosclerotic disease
DE102007006663A1 (de) * 2007-02-10 2008-08-21 Lts Lohmann Therapie-Systeme Ag Transport von Arzneistoffen über die Blut-Hirn-Schranke mittels Apolipoproteinen
US7985727B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
US8101565B2 (en) * 2007-09-20 2012-01-24 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8044021B2 (en) 2007-09-20 2011-10-25 Abbott Cardiovascular Systems Inc. Sustained release of apo A-I mimetic peptides and methods of treatment
US9173890B2 (en) 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
AU2009293019A1 (en) 2008-09-19 2010-03-25 Tandem Diabetes Care Inc. Solute concentration measurement device and related methods
BRPI1008628A2 (pt) * 2009-02-18 2016-03-01 Cormatrix Cardiovascular Inc método de tratamento ou prevenção de arritmia cardíaca em um indivíduo
AU2010217760B2 (en) 2009-02-27 2015-04-09 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
US9250106B2 (en) 2009-02-27 2016-02-02 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
WO2010105081A1 (fr) * 2009-03-13 2010-09-16 Medtronic, Inc. Procédé de traitement d'insuffisance cardiaque
EP3284494A1 (fr) 2009-07-30 2018-02-21 Tandem Diabetes Care, Inc. Système de pompe à perfusion portable
US10525152B2 (en) 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
AU2010315535A1 (en) 2009-10-26 2012-05-03 Cardiokinetix, Inc. Ventricular volume reduction
MX2012014928A (es) 2010-06-30 2013-03-22 Csl Ltd Una formulacion de lipoproteina de alta densidad reconstituida y metodo de produccion de la misma.
CN103068369A (zh) 2010-08-30 2013-04-24 霍夫曼-拉罗奇有限公司 产生四连蛋白-载脂蛋白a-i颗粒的方法，由此获得的脂质颗粒及其应用
EP2611419A2 (fr) 2010-08-30 2013-07-10 F.Hoffmann-La Roche Ag Procédé de production d'une particule lipidique de la teranectine-apolipoprotéine a-1, particule lipidique elle-même et son utilisation
MX2013002145A (es) 2010-08-30 2013-04-03 Hoffmann La Roche Tetranectina-apolipoproteina a-i, particulas lipidicas que la contienen y utilizacion de la misma.
EP2673296B1 (fr) * 2011-02-07 2018-10-24 Cerenis Therapeutics Holding SA Complexes de lipoprotéines, leur production et leurs utilisations
CN107854478A (zh) * 2011-04-27 2018-03-30 Ionis制药公司 载脂蛋白ciii（apociii）表达的调节
WO2012162392A1 (fr) 2011-05-23 2012-11-29 Timothy Hla Matériaux protecteurs de l'endothélium et procédés d'utilisation
BR112013033562A2 (pt) 2011-08-25 2017-02-14 Hoffmann La Roche proteína de fusão de tetranectina-apolipoproteína a-i encurtada, uma partícula de lipídio que a contém e uso das mesmas
PL2793913T3 (pl) * 2011-12-21 2023-11-06 Csl Limited Schemat dawkowania dla formulacji apolipoproteiny
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9555186B2 (en) 2012-06-05 2017-01-31 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
WO2014011908A1 (fr) 2012-07-11 2014-01-16 Esperion Therapeutics, Inc. Mélanges d'apolipoprotéine
US9125943B2 (en) 2012-11-02 2015-09-08 Csl Limited Reconstituted HDL formulation
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
US10017551B2 (en) 2013-03-15 2018-07-10 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux
TR201808189T4 (tr) * 2013-10-31 2018-07-23 Novo Nordisk As İğne kanülüne sahip enjeksiyon cihazı.
RU2017114607A (ru) 2014-09-28 2018-10-29 Кардиокинетикс, Инк. Устройства для терапии нарушений функции сердца
US10668015B2 (en) * 2015-01-20 2020-06-02 Incarda Therapeutics, Inc. Unit aerosol doses for anticoagulation
BR112018002123A2 (pt) * 2015-08-25 2018-09-11 Novo Nordisk A/S dispositivo médico para injeção com uma câmara de limpeza
DE102018107407A1 (de) 2017-03-28 2018-10-04 Edwards Lifesciences Corporation Positionieren, einsetzen und zurückholen von implantierbaren vorrichtungen
JP6784973B2 (ja) * 2017-03-30 2020-11-18 国立研究開発法人産業技術総合研究所 単層カーボンナノチューブ

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9103701D0 (sv) 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
US5520912A (en) * 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
US6306433B1 (en) * 1997-08-12 2001-10-23 Pharmacia Ab Method of preparing pharmaceutical compositions
US6287590B1 (en) * 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
AU2002362612B2 (en) 2001-09-28 2007-11-15 Cedars-Sinai Medical Center Prevention and treatment of restenosis by local administration of drug
BR0310100A (pt) * 2002-05-17 2007-04-27 Esperion Therapeutics Inc métodos para tratar, prevenir ou reduzir a lesão de reperfusão isquêmica em um tecido ou órgão, e para prevenir ou tratar de uma condição associada com a privação de oxigênio, seguida por suprimento de oxigênio aumentado a um tecido ou órgão em necessidade disto
AU2003239489A1 (en) * 2002-05-17 2003-12-02 Esperion Therapeutics, Inc. Method of treating dyslipidemic disorders

Also Published As

Publication number Publication date
EP1677597B1 (fr) 2014-01-08
EA010134B1 (ru) 2008-06-30
ES2449719T3 (es) 2014-03-20
US7435717B2 (en) 2008-10-14
OA13272A (en) 2007-01-31
NZ545939A (en) 2008-08-29
AU2004284932A1 (en) 2005-05-12
HK1093869A1 (en) 2007-03-16
US20080293633A1 (en) 2008-11-27
CO5690611A2 (es) 2006-10-31
CA2542726C (fr) 2012-05-15
NO339456B1 (no) 2016-12-12
MXPA06004362A (es) 2006-09-04
RS20060273A (sr) 2008-09-29
JP2007509157A (ja) 2007-04-12
PE20050438A1 (es) 2005-06-14
KR20070110561A (ko) 2007-11-19
ECSP066516A (es) 2006-11-24
PA8615301A1 (es) 2005-09-28
IL174301A0 (en) 2006-08-01
US20050142180A1 (en) 2005-06-30
IL174301A (en) 2013-09-30
CA2542726A1 (fr) 2005-05-12
WO2005041866A2 (fr) 2005-05-12
AR046126A1 (es) 2005-11-23
AU2011202014B2 (en) 2012-06-14
WO2005041866A3 (fr) 2006-05-18
KR20100101710A (ko) 2010-09-17
EP1677597A4 (fr) 2011-08-24
GEP20094601B (en) 2009-02-10
KR20060080227A (ko) 2006-07-07
EA200600548A1 (ru) 2006-10-27
NO20062110L (no) 2006-07-18
AU2011202014A1 (en) 2011-05-26
CR8352A (es) 2007-03-02
EP1677597A2 (fr) 2006-07-12

Similar Documents

Publication Publication Date Title
MA28102A1 (fr) Formulations pharmaceutiques, methodes et schemas d'administration pour le traitement et la prevention des syndromes coronariens aigus
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
CY1111999T1 (el) Λακτοφερρινη στην αγωγη κακοηθων νεοπλασματων και αλλων υπερπλαστικων νοσων
MXPA04008068A (es) Metodo para administrar moleculas de glp-1.
DK1289517T3 (da) Farmaceutiske sammensætninger indeholdende cannabidiolderivater
CY1105349T1 (el) Θειαζολυλ-αναστολεις τυροκινασεων της οικογενειας tec
ATE246514T1 (de) Paclitaxel enthaltende arzneimittel
NO2007010I2 (no) Sitagliptin, eventuelt i form av et farmasøytisk akseptabelt salt
FI961438A0 (fi) beta-amyloidiproteiinituotannon estäjiä
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
CY1116463T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
DE602004027936D1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
DK1206474T3 (da) Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer
NO20045323L (no) Antistoffer
CY1107383T1 (el) Αναστολεις της φωσφολιπασης α2 του κυτοπλασμικου διαλυματος
EA200201276A1 (ru) Производные арилметиламина для использования в качестве ингибиторов триптазы
BG105302A (en) Means for improving cognition
GB0002336D0 (en) Medicaments
WO2002039994A3 (fr) Methodes de traitement et de prevention des calculs urinaires
ATE319473T1 (de) Melagatran zur behandlung von entzündungen
TNSN06114A1 (fr) Formulations pharmaceutiques, methodes et schemas d'administration pour le traitement et la prevention des syndromes coronariens aigus
CY1105545T1 (el) Θεραπεια στατινης για ενισχυση της διατηρησης νοητικης λειτουργιας
WO2005048993A3 (fr) Minimisation de l'oxydation des medicaments dans des formulations pharmaceutiques renfermant des excipients irradies
SE0004827D0 (sv) Therapeutic compounds
SE0203817D0 (sv) New composition